In preclinical models, ISM6200 demonstrated superior efficacy in Cushing’s syndrome and glaucoma. (IMAGE)

InSilico Medicine

In preclinical models, ISM6200 demonstrated superior efficacy in Cushing’s syndrome and glaucoma.

Caption

In a rat model of Cushing's syndrome, ISM6200 significantly alleviated insulin resistance and decreased blood pressure. Following 6-day treatment, insulin resistance levels were reduced by 68%, and blood pressure approached the levels observed in healthy control groups. Additionally, in the therapeutic glaucoma model, after 3 days of dexamethasone injection followed by 3 days of ISM6200 treatment, measurements revealed a significant decrease in intraocular pressure (IOP) in mice, providing clues for subsequent clinical development. 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.